A director at Abivax bought 17,728 shares at 0.000EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Virbac : Declaration of the number of shares and voti DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsDecember, 31 20248 390 660Gross total of voting rights : 12 707 315Net total* of voting rights : 12 691 249 Net total* = ...
Virbac : Déclaration d'actions et de droits de vote 12/2024 DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place cotation : Euronext ParisCompartiment ACode ISIN : FR0000031577 DATENombre total d’actions composant le capital socialNombre total de droits de vote31 Décembre 20248 390 660Total brut de droits de vote : 12 707 315Total net* de droits de vote : 12 691 249 Total net* = nombre total de droits de vote attachés au...
We are hosting our 28th ODDO BHF Forum in Lyon on 9 and 10 January 2025. In total, 211 companies will be presenting over the two days. In the following note, we provide some initial feedback from the companies on day 1. Out of the 104 feedbacks collected during the first day, 40 were clearly positive, 59 rather Neutral, and only 6 negative. Among the positive names, we would particularly highlight Accor, URW, Euronext, Bureau Veritas, Renke, ID Logistics, Roche Bobois, Ionos, Companie des Alpes...
EQS-News: ABIVAX / Key word(s): Study Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment 09.01.2025 / 17:35 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion expected in Q2 2025. Top-line results for the 8-week induction trial anticipated in Q3 2025, with 44-week ma...
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion expected in Q2 2025.Top-line results for the 8-week induction trial anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026.Blinded baseline characteristics align with pre-specified target po...
EQS-News: ABIVAX / Key word(s): Personnel Abivax Announces a Change to the Composition of its Board of Directors 23.12.2024 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in pati...
Abivax Announces a Change to the Composition of its Board of Directors Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced that Dr. Philippe Pouletty, representative of Truffle Capital, tendered his resignation as director o...
Virbac : Declaration of the number of shares and voting rights 11/2024 DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsNovember, 30 20248 390 660Gross total of voting rights : 12 707 824Net total* of voting rights : 12 691 ...
Virbac : Déclaration d'actions et de droits de vote 11/2024 DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place cotation : Euronext ParisCompartiment ACode ISIN : FR0000031577 DATENombre total d’actions composant le capital socialNombre total de droits de vote30 Novembre 20248 390 660Total brut de droits de vote : 12 707 824Total net* de droits de vote : 12 691 758 Total net* = nombre total de droits de vote attachés au...
Virbac: Türkiye: Virbac acquires its companion animal distributor On December 2, we finalized the acquisition of Turkish company Mopsan, specialized in the distribution of petfood and companion animal health products. Present in Türkiye for over 20 years via various local distributors, then with our own subsidiary since 2018, we are today taking a new step forward with the acquisition of our companion animal products distributor: Mopsan. Working alongside Turkish veterinarians for over 30 years, Mopsan has extensive experience in the petfood and companion animal health products sector, a f...
VIRBAC: Turquie : Virbac acquiert son distributeur de produits pour animaux de compagnie Le 2 décembre, nous avons finalisé l'acquisition de la société turque Mopsan, spécialisée dans la distribution d’aliments et produits de santé pour animaux de compagnie. Présent en Turquie depuis plus de 20 ans via différents distributeurs locaux puis avec une filiale en propre depuis 2018, nous passons aujourd'hui un nouveau cap avec l'acquisition de notre distributeur en produits pour animaux de compagnie : Mopsan. Aux côtés des vétérinaires turcs depuis plus de 30 ans, Mopsan a une longue expéri...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.